New drug ORB-021 enters early human testing for advanced cancers

NCT ID NCT06607939

Recruiting now Disease control Sponsor: Orionis Biosciences Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether a new drug called ORB-021 is safe and tolerable for people with advanced solid tumors who have no standard treatment options left. About 36 adults will receive the drug through an IV to find the best dose for future studies. The main goal is to check for side effects and determine a safe dose, not yet to prove the drug works against cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ORB-021
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early phase 1 trial with only 36 participants, focused on safety and dosing. It is too soon to know if ORB-021 will effectively shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Honor Health Clinical Research
RECRUITING

Scottsdale, Arizona, 85258, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
MDAC
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.